The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hmmmm. Even more blocks today. Somebody taking advantage of the Arix stupidity.
LAST FIVE PUBLISHED TRADES
Time/date of execution Price Currency Volume Trade value* Trade type Trade flags MIC
15:48:36 22-Jan-2020 60.00 GBX 50,000 30,000.00 Off-book LRGS AIMX
15:48:45 22-Jan-2020 60.00 GBX 25,000 15,000.00 Off-book LRGS AIMX
15:56:39 22-Jan-2020 60.00 GBX 2,000 1,200.00 Off-book AIMX
15:37:44 22-Jan-2020 58.50 GBX 4,000 2,340.00 Off-book AIMX
15:27:13 22-Jan-2020 58.50 GBX 4,119 2,409.61 Off-book AIMX
Morning
So looks like it's the UK Aim market that sets the tone and the Nasdaq follows. From what you are saying that is not the norm.
What we need from VRP is some good positive news about interest in partnering the Phase III trial or a deal with a big pharma on the Dry Powder Inhaler.
"One day Rodney, one day".
Chester.
Well, not to burst anyone's bubble but there are distinct characteristics associated with US biotech stocks not usually seen with any other sector. First, as you all know, US bios tend to get rewarded handsomely for successful trials, NDA's, FDA special designations. The market tends to price in FULL success of a drug approval by FDA and it's estimated sales in most respects. That's why when you see any bios gets FDA approval for a drug, there is rarely any fanfare, or it even goes lower because it was already priced for that milestone. As you also know, if a trial fails, or it shows any adverse events, the market punishes that stock severely. Usually it's in the 30%-90% range depending on whether they will back up and refile, or whether they will abandon the drug altogether.
The other important point here is financing. The bigger companies with $1-$10 bil market cap tend to go higher when financing is announced. The mindset is that the money will carry their best prospect through to FDA approval. However, when a low capitalization stock does financing, it usually gets manipulated downward severely by short sellers screaming dilution.
The last important thing to remember. Biotechs very rarely care whether the market is up or down like the market. The pattern for the past year as the US markets continue to keep setting new highs is the biotechs are down overall. When the market sees profit taking, traders tend to move over to oversold biotechs.
The US Futures are up substantially tonight. That is good if you're in to tech stocks.
Ho Bio
No manipulation as the indicated share price is always the mid point of the spread. In this case it was 58p no conspiracy just how it's done.
The important thing is tomorrows opening price seeing as the Nasdaq closed strong at $6.42 which is really good to see.
The share price should be £1.00 minimum and we could get there over the next couple of weeks as people begin to reposition awaiting for the next news update.
Chester.
Did you all take note of the last five published trades today?
Time/date of execution Price Currency Volume Trade value* Trade type Trade flags MIC
16:28:41 21-Jan-2020 60.00 GBX 25,000 15,000.00 Off-book LRGS AIMX
17:08:25 21-Jan-2020 58.00 GBX 6,500 3,770.00 Off-book XOFF
16:16:49 21-Jan-2020 60.00 GBX 2,500 1,500.00 Off-book AIMX
15:28:12 21-Jan-2020 60.00 GBX 10,000 6,000.00 Off-book AIMX
15:20:46 21-Jan-2020 59.80 GBX 1,852 1,107.50 Off-book AIMX
Yet it says the high of day was 58. Yup. Even more manipulation
it would appear somebody with some common sense woke up stateside. Up 16%. At least it's a start.
A couple of other biologic companies are soaring in the states today on being granted FDA Fast Track status while still in Phase 1 & early Phase 2. One even 300$ higher. I've been looking here for the same designation for Ensifentrine and cannot find anything. I will say this. Any drug therapy that provides a dual purpose and also provides quality of life is always approved by the FDA for Fast track and/or Breakthrough Therapy designations. Has JAK indicated anywhere that those applications have been made and are pending? And also, where does Ensifentrine stand on any special EMA designations? Thanks
looks like we are set for another trip to the trough of plenty by the MM's
Good research Biohunter,
We are more or less back where we were prior to the recent very strong RNS. The share price was obviously manipulated both sides of the pond.
Not sure which market leads or follows but what I can see in the UK is that confidence in VRP has been knocked very severely.
I've bought shares in Verona for six years and many have been involved for as long as 12 years. Along that road there have been many bumps and disappointments but this recent fantastic data release should have been the catalyst to a much higher SP.
The fact that we were all out manoeuvred and any new money over 70p just snatch away by in the know traders has left a bad feeling. I'm now of the opinion that only news of a partner plus FDA agreement on Phase III is going to move us to where we should actually be .
Chester.
+4.20. Like I said, big boy eyes are watching and they've had enough of the BS
OK. I get it. This is really just a ruse here and nobody knows wth is going on. Why no answers to my questions...and they are legitimate. One thing I did just come across though. Orbimed holds a large stake in VRP right behind Novo. They also came in large in the states on VRNA. Orbimed is also one of the largest holders of ADVM in the states. Not long ago ADVM broke out on WetMD data up above $15. Then, follow on data was released in the $12's on the same data that was "misinterpreted" and that took it down to the $4.90's. Next thing you know it is right back over $12. My point is it all appears to have been orchestrated and Orbimed cashed huge. I have the distinct feeling Orbimed is very active behind the scenes and couldn't give a flip what Arix/Arthurian does. They are extremely small & laughable fish in the grand scheme of things. I wouldn't be surprised to see Orbimed pull the same exact reversal and run up on VRP/VRNA. IMO they now control both sides of a stocked pond.
Newbie...lol
I see here from reading more you think management might be watching. Good for them! I hope they are! I would think more important is that 87 million VRP shares held by a dozen folks would be watching more.
If ALL of you are in at higher prices, or somehow hedged your position with the US IPO at $13.50, then why on earth did you ignore the $3's? With this recent news why are you ignoring the $5's? Only an institutional fool would dump an 80-100 pence stock in the 50's and 60's on good news. These money managers scream all day long to buy low and sell high and it would appear they are doing the complete opposite on nothing but good news.
This really becomes a visibility issue. With all the under $100 million market cap biotech in the US running 100%-1000% on far, far lesser news and trial updates, somebody clearly didn't get the message how severely undervalued VRP and of course VRNA are.
Newbie so go easy on me OK? I've been looking this over and quite frankly just don't understand the response to supposed great trial news last week. So, let me get some questions out of the way.
1. Who leads this show? The cart or the horse? Does US trading automatically follow LSE trading? Or vice versa? Seems to me if LSE leads with continual 5-6 pence spreads, or 10%+, it can and appears to lead to much manipulation
2. I've looked and looked. What caused the recent spike over a pound? Was it staged to give Axis room to unwind?
3. What do you make of the Axis unwinding on good news? Is this an internal issue with Axis that has nothing to do with VRP? Are they market timing? Why are the others like Novo, Rothschild/Andera, Orbimed, Growth Equity not stepping up to provide a floor?
4. I see where Wedbush put their money where their mouth is in stepping up their position from 30K shares to over 80K shares on the news of their own $60 price target. It makes me think they bought Axis shares without knowing it even though two different exchanges. Any ideas why these guys aren't getting together to negotiate these block sales as gray area transfers like in the US rather than open market selling?
TIA. That's it for now.